Early Development and The Dose Selection in the Immune-oncology

The Effective Statistician - in association with PSI

The Effective Statistician - in association with PSI

Content provided by Alexander Schacht and Benjamin Piske, biometricians, statisticians and leaders in the pharma industry, Alexander Schacht, Benjamin Piske, and Leaders in the pharma industry. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Alexander Schacht and Benjamin Piske, biometricians, statisticians and leaders in the pharma industry, Alexander Schacht, Benjamin Piske, and Leaders in the pharma industry or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

about a year ago 21:59

AAC•Episode home

Interview with Teppo Huttunen

Key points:

Dose Selection Challenge
Limitations of 3+3 Design
BOIN Design
Backfilling
Efficacy vs. Safety
Statisticians’ Role
Practical Challenges
FDA Guidance
Cross-Functional Approach
Industry Trends
Cost & Timeline Estimation

Understanding dose selection in immune-oncology is crucial for developing safer and more effective treatments, and statisticians play a central role in driving these decisions.

In this episode, Teppo shares practical insights into overcoming the limitations of traditional methods and adopting more flexible approaches like the BOIN design.

If you want to stay ahead in oncology research and learn how to balance safety, efficacy, and practical challenges in dose optimization, this episode is a must-listen!

444 episodes

#Natural Sciences #Statistics #Biostatistics #Pharmaceutical #Benjamin Piske #Alexander Schacht #Leaders in the pharma industry #Data Science #Science #Psy

The Effective Statistician - in association with PSI